c-kit mutation and clinical outcome, a larger group of patients is necessary.
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TO THE EDITOR
We read with interest the recent correspondence by Tedeschi et al 1 describing an arsenic-induced molecular remission in a patient with relapsed promyelocytic leukemia (APML) postallograft. 1 In this patient, the duration of complete remission (CR) from initial remission to relapse preallograft was 12 months, from allograft until relapse was 11 months and postarsenic was 14 + months. We describe a patient, now 10.5 years since the initial diagnosis of APML, in ongoing remission for 36 months postarsenic for third relapse after an allograft.
APML with t(15;17) was diagnosed in a 27-year-old female in July 1992. CR was achieved with all-trans retinoic acid (ATRA) and followed by consolidation chemotherapy with daunorubicin and cytosine arabinoside (ara C).
She relapsed 3 years after the initial diagnosis. CR2 was achieved with ATRA and an allograft from a histocompatible brother using peripheral blood progenitor cells (PBPC) and busulfan-cyclophos- phamide conditioning was performed in January 1996. No acute graft versus host disease (GVHD) occurred despite a rapid taper of cyclosporine (ceased d63). A second relapse occurred 11 months post-transplant. ATRA was ineffective; she then received two cycles of idarubicin 12 mg/m 2 daily for 3 consecutive days. CR3 was documented after the first cycle, with cytogenetics showing only normal male metaphases. The second cycle was followed by the infusion of unmodified PBPC from her donor without GVHD prophylaxis and interferon alfa-2b 1-3MU three times weekly at count recovery. This was complicated 2 months later by significant cutaneous oral and vaginal GVHD; interferon was ceased.
A third relapse occurred in January 2000, 35 months after CR3. The marrow blast percentage was greater than 90%, characteristic of all the previous relapses. Cytogenetic evolution was documented, with the appearance of abnormalities of chromosomes 8 and 21, not previously recognized, in addition to t(15;17). ATRA and idarubicin were ineffective. She then received arsenic 10 mg i.v. daily for 28 days each alternate month for seven cycles. A single dose of 500 mg araC was given with the first cycle and ATRA 70 mg total daily dose was given concomitantly with arsenic for the remaining six cycles. Treatment was complicated by a sensory peripheral neuropathy. Morphological remission was obtained after the first cycle. Cytogenetics were unsuccessful after the first two cycles; a normal male (donor) karyotype was demonstrated after the third cycle. Serial marrows subsequently have demonstrated ongoing CR4 by cytogenetic and since April 2001 by molecular criteria, the latter initially using a qualitative RT-PCR assay (sensitivity one in 10000) for PML/RARa transcripts. The latest assessment was in February 2003, 37 months after her third relapse. A quantitative RT-PCR assay (sensitivity one in 10000) was negative. Donor-only cells were detected by cytogenetics; FISH analysis showed normal arrangement of the PML and RARa genes in 416 cells.
This case is notable for a number of features. Firstly, it describes an unusual pattern of multiple late relapses over 8 years in a patient with APML. Series with long-term follow-up of APML suggest that late relapses are relatively uncommon. 2 Secondly, the third relapse occurred despite significant extensive chronic GVHD after the reinfusion of donor stem and T cells without GVHD prophylaxis. While the duration of the CR after this reinfusion was longer than the initial CR post-transplant, suggestive of graft vs APML effect, this may have been due to concomitant idarubicin therapy that was not given for the relapse immediately pretreatment. 2 To our knowledge, the unequivocal existence of a graft vs APML effect, such as a durable remission of relapsed APML postallograft occurring after the withdrawal of immunosuppression or the infusion of donor leukocytes without concomitant chemotherapy, has not been reported in the literature. A lower relapse rate for allografts vs autografts in CR2 has been reported in abstract form (Sanz MA et al. Blood 2000; 96: 11; abstract 2247), but updated results from the European APML group suggest that relapse due to infusion of molecularly positive autologous cells may explain this observation (De Botton S et al. Blood 2002; 100: 11; abstract 816). These latter results demonstrated a high rate of durable remission in patients autografted in CR2 using cells without molecular evidence of disease and suggest that myeloablative conditioning may be more important than a graft vs APML effect in eradicating disease in the transplant context.
Recent literature has highlighted the utility of molecular monitoring for PML / RARa transcripts in APML. 3 Monitoring of this type was not available until after the third relapse in our patient. It is likely that regular molecular monitoring would have detected relapse earlier than hematological relapse and early intervention at that point would have minimized the morbidity associated with reinduction treatment in a patient with florid disease. 4 We now routinely follow our APML patients, treated with chemotherapy alone or post-transplant for relapsed disease, with molecular monitoring. 5 Arsenic achieves a high rate of CR in patients with relapsed APML who have not been previously transplanted, with an estimated relapse-free survival of 56% at 18 months. 6 Our patient is in hematological remission almost 3 years after arsenic and ATRA and has exceeded the longest duration of any previous remission. It is worth noting that she responded to arsenic without ATRA for the first cycle, having been resistant to idarubicin/ATRA the previous month. We elected subsequently to use arsenic in combination with ATRA based on in vivo evidence in a mouse model that they may synergize in eradicating leukemia cells. 7 Whether this combination is superior to arsenic alone has not, to our knowledge, been clearly established in the clinical setting.
Further experience is required to determine if the optimal therapy for relapsed APML postallograft is arsenic7ATRA, immunomodulation or a combination of both. Our approach is to use quantitative PCR to guide management. Patients with confirmed molecular-only relapse who have not had significant GVHD have withdrawal of immunosuppression and/or donor leukocyte infusion; arsenic is reserved for patients who do not respond to this approach or those with hematological relapse. 
